摘要
目的:分析替诺福韦在乙型肝炎表面抗原(HBsAg)阳性孕妇母婴阻断中的应用效果。方法:选取2022年1月—2023年4月赤水市妇幼保健院产科收治的HBsAg阳性孕妇100例作为研究对象,依据随机数字表法分为对照组与观察组,各50例。对照组予以替比夫定治疗,观察组予以替诺福韦治疗。比较两组孕妇乙型肝炎病毒(HBV)DNA载量、丙氨酸氨基转移酶(ALT)水平、不良反应情况及婴儿HBV-DNA、HBsAg阳性率。结果:治疗前,两组孕妇HBV-DNA载量、ALT水平比较,差异无统计学意义(P>0.05);治疗后,两组孕妇HBV-DNA载量、ALT水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。出生时与出生6个月后,观察组婴儿HBV-DNA、HBsAg阳性率低于对照组,差异有统计学意义(P<0.05)。结论:替诺福韦在HBsAg阳性孕妇母婴阻断中的应用效果理想,可降低孕妇HBV-DNA载量、ALT水平,降低婴儿HBsAg、HBV-DNA阳性率,且未增加不良反应。
Objective:To analyze the effect of tenofovir in blocking maternal and infant hepatitis B surface antigen(HBsAg)positive pregnant women.Methods:A total of 100 HBsAg positive pregnant women were selected as the study objects at the obstetrics Department of Chishui Maternal and Child Health Care Hospital from January 2022 to April 2023,and were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was treated with telbivudine and the observation group was treated with tenofovir.Hepatitis B virus(HBV)DNA load,alanine aminotransferase(ALT)level,adverse reactions and infant HBV-DNA and HBsAg positive rates were compared between the two groups.Results:Before treatment,there was no significant difference in HBV-DNA load and ALT level between the two groups(P>0.05).After treatment,the HBV-DNA load and ALT level of the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).At birth and 6 months after birth,the positive rate of HBV-DNA and HBsAg in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion:Tenofovir has an ideal effect in the application of mother-to-child blocking in HBsAg positive pregnant women,which can reduce the HBV-DNA load and ALT level in pregnant women,and reduce the positive rate of HBsAg and HBV-DNA in infants,without increasing adverse reactions.
作者
袁家会
Yuan Jiahui(Chishui Maternal and Child Health Care Hospital,Chishui 564700,Guizhou province,China)
出处
《中外医药研究》
2024年第6期48-50,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
